ArticleTaiwan journal of ophthalmology
Diffuse choroidal hemangioma: IMRT versus episcleral plaque brachytherapy.
Article in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Laser Indirect Ophthalmoscopy-Guided Transpupillary Thermotherapy Versus I-125 Plaque Brachytherapy for Choroidal Hemangioma.Cancers · 2025Article
- Ocular oncology: Rare and amazing.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this review is to demonstrate the safety and procedures involved in the use of intensity-modulated radiation therapy (IMRT) and three-dimensional (3D)-conformal techniques for the management of diffuse choroidal hemangioma (DCH) and to compare dosimetric outcomes of these techniques to simulated episcleral plaque brachytherapy in the same cohort of 10 patients (11 eyes) with DCH. MATERIALS AND
methodsA single institutional retrospective review of patients with Sturge-Weber syndrome associated DCH managed with IMRT (20 Gy in 10 fractions). Those same patients were planned for simulated brachytherapy and simulated doses to the fovea, disc, and lens were collected. The dose to organs at risk (critical visual and surrounding structures) was compared to determine potential long-term risks.
resultsTen patients (11 eyes) examined in this review were treated between 2005 and 2023. The use of IMRT and 3D allowed for effective coverage of the planning target volume (PTV) with low doses to critical visual and surrounding structures. Doses to the fovea, disc, and lens using external beam radiotherapy (EBRT) were uniform ranging from 1784 to 2151 cGy, 1695-2204 cGy, and 260-1579 cGy, respectively. Doses to the fovea, disc, and lens using episcleral plaque brachytherapy had ranged from 270 to 12270 cGy, 20623829 cGy, and 270-618 cGy, respectively.
conclusionIMRT and 3D-conformal technique used to deliver 20 Gy in 10 fractions provides a uniform safe plan in patients with DCHs with reasonable sparing of the lens, fovea, and optic disc. Simulated brachytherapy yielded variable radiation exposure to critical visual and surrounding structures with potential risk of vision-threatening toxicity. Use of EBRT or brachytherapy should be considered on a case-by-case basis driven by estimated radiation dosimetric parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.